<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3079">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788501</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCP_001</org_study_id>
    <nct_id>NCT01788501</nct_id>
  </id_info>
  <brief_title>Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease</brief_title>
  <official_title>Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare efficacy and safety of tacrolimus/methotrexate with
      cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic
      hematopoietic stem cell transplantation patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of grade II-IV acute graft versus host disease</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall grade I graft-versus-host disease denoted stage 1 to 2 skin involvement with no liver or gut involvement. Overall grade II graft-versus-host disease  denoted stage 3 skin involvement or stage 1 liver or gut involvement. Overall grade III graft-versus-host disease  denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement without graft-versus-host disease as a major contributing cause of death. And Overall grade IV graft-versus-host disease denoted stage 4 skin involvement or stage 2 to 4 liver or gut involvement with graft-versus-host disease as a major contributing cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of infection</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Fever would be categorized as fever occured before engraftment and after engraftment. If microbiologically documented, pathogen would be specified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse drug reactions</measure>
    <time_frame>day 100 post transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>adverse drug reactions would be measured by Common Terminology Criteria for Adverse Events v3. And for determinating the likelihood of whether an adverse drug reaction is actually due to the drug, Naranjo algorithm would be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)
Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)</description>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push</description>
    <arm_group_label>Tacrolimus/Methotrexate</arm_group_label>
    <arm_group_label>Cyclosporine/Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of hematological malignancy

          -  Age under 18 years old

          -  Serum bilirubin less than 1.5 X upper limit of normal

          -  Aspartate transaminase, Alanine transaminase less than 2.5 X upper limit of normal

          -  Alkaline phosphatase less than 2.5 X upper limit of normal

          -  Serum creatinine less than 1.5 X upper limit of normal

          -  Agrees to participate, and informed consent signed

        Exclusion Criteria:

          -  Evidence of HIV infection

          -  Documented uncontrolled disease (infections)

          -  Prior transplantation (hematopoietic stem cell or solid organs)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JungMi Oh, Pharm.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MyeongGyu Kim</last_name>
    <phone>82-2-2072-0335</phone>
    <email>onskydream1@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
      <phone>82-10-7650-2656</phone>
      <email>onskydream1@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>HyoungJin Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
      <phone>82-10-7650-2656</phone>
      <email>onskydream1@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>KyoungNam Ko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
      <phone>82-10-7650-2656</phone>
      <email>onskydream1@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>KeonHee Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyoung Jin Kang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
